RE:RE:RE:New Press Release - Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian CancerCan't trust the CRO. Can't outsource to an emplooye of a CRO the importance of this study. It's the VPs and P job to do so, relentlessly. They have a Montreal site, likely a few miles from their head-office. They need to be in there every week. Every freakin' week. NO excuses. No more excuses.